Animal models that faithfully recapitulate clinical features of myelodysplastic syndrome (MDS) have been difficult to establish. MDS are hematologic disorders associated with ineffective hematopoiesis, blood cytopenias, myeloid dysplasia and an increased risk of acute myeloid leukemia (AML). Although transplantation of primary AML cells into immunocompromised mice has been met with much success, primary MDS patient samples exhibit poor engraftment with no evidence of disease in recipient animals. [1] [2] [3] The engraftment of primary MDS samples is complicated further by frequent outgrowth of normal HSC clones. 4 These challenges underscore the current limitations and inefficiencies of engrafting primary MDS cells. Recent improvements in engrafting primary MDS cells have been observed when transplanting immunophenotypically defined HSC from the marrow of MDS patients or when co-injecting stromal cells engineered to produce non-cross-reacting human cytokines. 5, 6 Unfortunately, even with the improved engraftment of primary MDS cells, mice do not succumb to features resembling human MDS, precluding the use of these models for pre-clinical testing. To circumvent the current limitations, we developed a model using immunocompromised recipient mice and a human MDS cell line (MDSL) derived from the non-leukemic phase of an MDS patient with refractory anemia-ringed sideroblasts. [7] [8] [9] The MDSL line was derived as a subline of MDS92, and maintains factor dependency for cell growth, but has reduced differentiational capacity compared with MDS92. 10 Herein, we report the successful engraftment of MDSL cells into NOD/SCIDIL2Rg mice (NSG) and NSG-hSCF/hGM-CSF/hIL3 (NSGS) mice, and reproducible development of disease, including cytopenias, clonal expansion and host hematopoietic suppression. In addition, we show that the MDSL xenograft model is a useful tool for evaluating novel and existing therapeutics for MDS.
As reported for the original parental MDS92 line, 11 MDSL cells have maintained cytokine dependence in vitro. Upon hIL-3 withdrawal, MDSL cells stop growing within three days and die within five days (Figure 1a) . Given the challenges of engrafting primary human MDS samples, we sought to determine the engraftment and diseaseinitiating potential of MDSL. A total of 1 Â 10 6 MDSL cells were injected intravenously into 8-10 week old sub-lethally irradiated NSG or NSGS mice, and mice were monitored for evidence of hematopoietic malignancy. MDSL engraftment in NSGS or NSG resulted in a fatal hematologic disease associated with cytopenia, marrow failure and organ infiltration, with a median survival of 24 and 70 days post injection, respectively (Figure 1b) . The shorter latency observed with the NSGS is attributed to the transgenic expression of three non-cross-reacting human cytokines (SCF, GM-CSF and IL3), which provide an enhanced milieu for the myeloid cell grafts. 12 At the time of killing, flow-cytometric analysis revealed efficient MDSL engraftment of hCD45 þ cells in the bone marrow (BM), spleen (SP) and the peripheral blood (PB) of both NSG and NSGS recipient mice (Figure 1c) . Interestingly, conditioning NSG or NSGS mice with sub-lethal radiation was not requisite for MDSL cell engraftment, however non-irradiated recipients did exhibit a delayed disease latency (data not shown).
Intrafemoral BM aspirates of NSG at 53 days post transplant revealed an average human MDSL (CD45 þ CD33 þ ) graft of 2% total marrow (Figure 1d) . However, at time of death (82 days post transplant), MDSL cells progressively expanded to occupy B60% of the total marrow (Figure 1d ). BM cellularity was determined for MDSL-and CD34
þ cord blood-engrafted NSG mice 10 weeks post transplant. Although MDSL cells gradually expanded over time, the total cellularity of MDSL-engrafted marrows was 70% less than CD34
þ cord blood-engrafted marrows (5 Â 10 6 versus 22 Â 10 6 cells/femur) (Figure 1e ). Immunohistochemical examination of the BM from MDSL-engrafted NSG mice confirmed a hypocellular marrow, whereas control CD34 þ cell-engrafted mice exhibited normal BM cellularity ( Figure 1f ). In MDSL-engrafted mice, we also observed bone remodeling at the endosteum (Figure 1f ). These findings indicate that MDSL cells undergo clonal expansion whereas simultaneously displacing host-mouse BM cells.
To examine subclonal selection following transplantation, MDSL cells were immunophenotypically evaluated for the expression of hematopoietic stem/progenitor and myeloid cell markers immediately before transplantation ( Figure 1g and disease latency was not significantly different from primary transplantations (data not shown). Collectively, these observations suggest that minimal subclonal selection and immunophenotypic evolution occurs in MDSL xenografts.
We chose to further characterize NSG animals, as they presented with a predominant BM graft that might more closely represent human disease pathology in MDS. To investigate the consequences of MDSL xenografts on host-mouse hematopoiesis, recipient NSG mice transplanted with MDSL or control CD34 þ cells were monitored by complete blood count analysis. By 10 weeks, mice xenografted with MDSL cells exhibited reduced mouse red blood cells (P ¼ 0.04), hemoglobin levels (P ¼ 0.02) and platelet counts (P ¼ 0.07) as compared with mice transplanted with CD34 þ cells (Figure 1j ). This observation suggests that the MDSL cell graft impairs mouse hematopoiesis resulting in anemia and thrombocytopenia. Next we tested the MDSL xenograft model as a pre-clinical tool for examining drug efficacy. Lenalidomide (LEN) is FDA approved for first-line treatment of low-risk del(5q) MDS, 13 and MDSL cells have been reported to be sensitive to LEN in vitro. 8 For these reasons, we believed that LEN would be an ideal therapeutic agent to test our experimental system. Consistent with previous reports, in vitro treatment of MDSL with 10 mM LEN resulted in increased apoptosis (as measured by Annexin V/PI staining; Figure 2a ) and reduced growth (as measured by trypan blue exclusion; Figure 2b) . Furthermore, the effect of LEN on progenitor function was evaluated using the methylcellulose assay. MDSL cells formed Figure 2f ). Taken together, these data suggest that LEN is capable of suppressing the MDSL clone both in vitro and in the in vivo setting provided by our xenograft model.
In the present study, we examined the ability of NSG and NSGS mice to support the growth of an MDS patient-derived cell line. Phenotypic characterization of MDSL has revealed that they retain the dysplastic, non-blast like morphology in vitro and in vivo. Unlike AML cell-line xenografts, the MDSL graft does not undergo clonal selection, and does not exhibit shortened disease latency, following secondary transplantation. Thus our findings highlight the relevance of this model to MDS. Although there are notable limitations of using a single cell-line-based xenograft system to extrapolate human disease and pre-clinical assessment of therapeutics, several important advantages exist. Mice transplanted with MDSL exhibit efficient engraftment, which permits serial tracking of the MDS clone, and develop a fatal disease. Importantly, certain hematopoietic parameters of MDSL-xenografted mice, namely anemia and thrombocytopenia, mirror features associated with human MDS.
Following transplantation of MDSL, both NSG and NSGS animals displayed human cell grafts, however the disease features occurred in NSGS animals with a significantly shortened latency. The accelerated disease in NSGS xenografted mice suggests that the transgenic expression of hGM-CSF, hSCF and hIL3 enhances growth and survival of the MDSL cells in vivo. Given that both NSG and NSGS mice permit efficient engraftment of MDSL cells into the marrow, yet with different kinetics, this model provides a platform to study niche interactions and the inter-relationship between MDS cells and the host-marrow environment. Interestingly, the hypoplastic marrow subtype of MDS (B15% of all cases) is typically associated with immune-mediated pathogenesis, with increased levels of pro-inflammatory cytokines.
14 Our MDS model generates a hypocellular marrow environment and thus provides an opportunity to potentially examine this disease variant in greater detail.
In addition, MDSL cells are capable of engrafting into immunodeficient recipients without the use of radiation, thus making these animals amenable to treatment with traditional combination chemotherapies. Evaluating chemotherapies within this model system would be otherwise impossible if radiation pre conditioning was required for MDSL engraftment. 15 In particular, the short-disease latency of this model provides an opportunity for a timely experimental readout in pre-clinical MDS studies. Moreover, the anemia and thrombocytopenia exhibited by this model provide readily measurable secondary endpoints when assessing the disease-modifying activity of novel agents in vivo. In summary, given the faithful recapitulation of an MDS-like phenotype and the rapid experimental disease readout, we believe that MDSL xenografts will become an important tool in studying the activity of novel agents designed for MDS. DTS is an ASH scholar and JCM is a leukemia and lymphoma scholar. T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell progenitors at various stages of development. 1 Although significant strides have been made in the treatment of pediatric T-ALL with more than 80% of the patients now being cured of their disease, 2 the early immature subtype of T-ALL has a dire prognosis with a 10-year overall survival of only 19%. 3, 4 Early immature T-ALL is characterized by a gene expression signature related to early T-cell precursors and a distinct immunophenotype: CD1a À , CD8 À , CD5 weak with expression of stem-cell/myeloid markers. 3, 4 In addition, this subtype of T-ALL harbors a distinct panel of mutations in genes that are commonly disrupted in acute myeloid leukemia. [4] [5] [6] Although the genetic lesions characterizing early immature T-ALL have recently been described, 6 the molecular basis underlying the inherent chemoresistance of this subtype of T-ALL remains largely unknown.
The high relapse rates of several lymphoid malignancies have been attributed to upregulation of anti-apoptotic BCL2 family members.
7 BH3 mimetics, a class of small molecules that mimic BH3-only pro-apoptotic proteins, engage pro-survival BCL2 family proteins to promote cell death.
8 Navitoclax (ABT-263) targets BCL-X L , BCL2 and BCLw; however, its use in the clinic has been limited because BCL-X L inhibition results in thrombocytopenia. [9] [10] [11] [12] ABT-199, an investigational drug in clinical trials, is a potent BCL2 inhibitor that has minimal activity against BCL-X L and thus does not affect platelet survival. 12 ABT-199 elicits striking pro-apoptotic effects as a single agent on non-Hodgkin's lymphoma cell lines and chronic lymphocytic leukemia primary Accepted article preview online 17 December 2013; advance online publication, 10 January 2014
